SomatoKine User Fee Goal Date Extended to Oct. 3, Insmed Says

The insulin-like growth factor therapy is under priority review for the orphan indication of growth hormone insensitivity syndrome. The original review deadline of July 3 is being extended to allow FDA time to review a major amendment to the NDA.